RWM
FULC icon

Rialto Wealth Management’s Fulcrum Therapeutics FULC Stock Holding History

Rialto Wealth Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Hold
159
– – ﹤0.01% 1037
2025
Q4 		$1.8K Hold
159
– – ﹤0.01% 783
2025
Q3 		$1.46K Hold
159
– – ﹤0.01% 773
2025
Q2 		$1.09K Hold
159
– – ﹤0.01% 819
2025
Q1 		$458 Buy
+159
New +$584 ﹤0.01% 933

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Rialto Wealth Management's FULC Position: Q1 2026 in Review

Rialto Wealth Management held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 159 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Rialto Wealth Management first reported a position in FULC in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.8K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Rialto Wealth Management held 159 shares of Fulcrum Therapeutics worth $1.22K as of Q1 2026.
  • Rialto Wealth Management left its Fulcrum Therapeutics share count unchanged in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1037 holding.
  • Rialto Wealth Management first reported a position in Fulcrum Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Rialto Wealth Management's Fulcrum Therapeutics position peaked at $1.8K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.